LABP-104 is under clinical development by Landos Biopharma and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LABP-104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LABP-104 overview

LABP-104 is under development for the treatment of rheumatoid arthritis and systemic lupus erythematosus. The therapeutic candidate is administered by oral route. It targets lanthionine synthetase C-like 2 (LANCL2).

Landos Biopharma overview

Landos Biopharma (Landos) is a biopharmaceutical company. It develops oral therapeutics for the treatment of autoimmune diseases. The company pipeline product includes LANCL2, NLRX1, PLXDC2BT-11 small molecule therapeutics for the treatment of anti-inflammatory disease. It utilizes Lanthionine Synthetase C-Like 2 (LANCL2) technology for developing their products. The company is engaged in the development of BT-11 and NX-13 for the treatment of UC and CD. The company serves in the therapeutic areas of inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Landos is headquartered in Blacksburg, Virginia, the US.

For a complete picture of LABP-104’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.